Naproxen,
does it really help with Relief of primary dysmenorrhea?
research showsNaproxen is rated B because it repeatedly reduced primary dysmenorrhea pain versus placebo. Twenty-one trials were included, and the 16 trials contributing to the drug-specific synthesis gave OR 3.67 (95% CI 2.94 to 4.58).
ads claimMarketing can imply a remedy for every menstrual or pelvic pain syndrome, whereas the evidence concerns short-term pain relief in primary dysmenorrhea without pelvic pathology.
Useful facts when choosing a product
- The Daniels trial distinguished 120 randomized participants from 85 efficacy completers.
- Naproxen also appears in verdict 795 for osteoarthritis, a different indication.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.naproxen.UNK.primary-dysmenorrhea.relieve.MULTIUnknown > Naproxen > Unknown > primary dysmenorrhea > Symptom-relief claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Whether naproxen reduces primary dysmenorrhea pain. Daniels randomized 120, treated 101, and used 85 efficacy completers. Active-control naproxen produced SPID-8 of 12.0 versus 7.9 and TOTPAR-8 of 20.3 versus 13.5 compared with placebo, both P<0.001. The primary comparison was valdecoxib versus placebo; naproxen was secondary. Cochrane included 21 naproxen-placebo trials, of which 16 contributed to the drug-specific synthesis, OR 3.67 (95% CI 2.94 to 4.58). Decisive trials lasted only hours to days, and the Daniels analysis included 85 of 120 randomized participants, giving B1. verdict 795, which is B with 70 points, concerns osteoarthritis and was not transferred. verdict 1034, which is B with 70 points, verdict 857, which is B with 75 points, and verdict 1833, which is C with 50 points, concern other interventions.
Why this is classified as B (70)
P, R2, I1, E+, and B1 derive B with 70 points.
Counterpoint. New, worsening, or noncyclic pain requires assessment for a secondary cause.
Rejudgment record. Cross-check applied — Replicated placebo-controlled efficacy with B1 for hours-to-days duration and efficacy analysis of 85 among 120 randomized participants
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R2 | Independently replicated across trials |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Total pain relief over eight hours | B | TOTPAR-8 was significantly higher than placebo. |
| Summed pain-intensity difference over eight hours | B | SPID-8 was significantly higher than placebo. |
| Moderate or excellent dysmenorrhea relief | B | Multiple trials repeatedly favored naproxen over placebo. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Daniels SE et al. 2005 | Randomized double-blind placebo- and active-controlled crossover trial | 120 randomized; 101 treated; 85 efficacy completers | Commercial funding from Pharmacia within a drug-development program | Eight-hour SPID and TOTPAR pain relief | Active-control naproxen SPID-8 was 12.0 versus 7.9 and TOTPAR-8 was 20.3 versus 13.5; P<0.001 versus placebo, but secondary | Direct acute efficacy |
| Marjoribanks J et al. 2015 | Cochrane systematic review and meta-analysis | 80 trials and 5,820 women; 21 naproxen-placebo trials | Academic Cochrane review; 59% of included trials commercially funded and 31% unreported | Moderate or excellent pain relief | Naproxen-specific synthesis of 16 trials: OR 3.67 (95% CI 2.94 to 4.58); 21 was the included-trial count | Replicated synthesis |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Naproxen x relief of primary dysmenorrhea — Evidence Grade B·70. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/naproxen-primary-dysmenorrhea-pain-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.